Public Policy Council
The Public Policy Council will guide the Center's policy-related strategy, identifying opportunities to apply research findings and informing the Center's overall policy objectives, activities, and priorities.
Nitzan Arad, LLM
Duke-Margolis Institute for Health Policy
Nitzan Arad, LLM
Duke-Margolis Institute for Health Policy
Nitzan Arad is an Area Lead for Drug Pricing with the Duke-Margolis Institute for Health Policy. Her work focuses on drug pricing and payment reforms, primarily in Medicare and Medicaid. Before joining Duke-Margolis, she was a Director of Public Policy at Teva Pharmaceuticals, where she led research and analysis on a variety of government pricing and reimbursement, intellectual property, trade policy and biosimilar issues, in the U.S. and international markets. She also interacted regularly with different industry associations and developed policy strategies to support company advocacy efforts on various topics.
David Bruhn, PharmD, MBA
Otsuka
David Bruhn, PharmD, MBA
Otsuka
As the Senior Director: Patient Experience Data & Clinical Outcome Assessments in the Global Integrated Evidence & Innovation group at Otsuka Pharmaceutical and Development Corporation, David Bruhn and his team are responsible for broad research and operations-related activities within the R&D organization, supporting the full Otsuka pipeline, with a focus on neuroscience, digital and nephrology.
Previously, he was Head of Health Economics & Outcomes Research (HEOR), Medical Affairs at Avanir Pharmaceuticals, where he was responsible for the early and timely translation of HEOR data for regulatory submissions, payer reimbursement and access. He applies HEOR data into evidence-based strategies, value messaging, customer facing tools, HTA, and formulary dossiers. Prior to joining Avanir, he was Executive Director of US Health Outcomes & Value at Allergan and Director of the US Regional Health Outcomes Liaisons at GlaxoSmithKline. In addition to working with large US payer organizations, he has designed and conducted health outcomes studies across multiple disease areas, with a focus in diabetes and neuroscience. He completed a 4-year term as an advisory panelist on the Patient Centered Outcomes Research Institute’s Improving Healthcare Systems Panel and provided BioPharma input into their program on comparative effectiveness research. He was previously a research advisor in the Global Health Outcomes organization at Lilly where he was responsible for the research and communication activities for exenatide. He was also an Outcomes Research Scientist supporting emerging and developed markets outside the US where his research centered on demonstrating value for diabetes therapeutics. As leader of the health outcomes liaison team, he partnered with large managed care organizations and state Medicaid as well as international government/HTA agencies on a variety of health outcomes research projects. Additionally, he helped develop several analytic tools to assist population health decision makers in understanding their medication utilization patterns and to improve medication efficiency and effectiveness. A biomedical-biochemical engineer by training, he completed a Doctor of Pharmacy and Master of Business Administration from USC.
He enjoys time spent outdoors at his home in San Diego, CA with his wife and four children. Weekends are usually spent cheering on girls’ and boys’ water polo games, cooking and grilling in the backyard, and succulent yardwork and gardening.
Rosa M. Colon-Kolacko, CDM, MBA, SHRM-SCP
Global Equity and Learning Partners
Rosa M. Colon-Kolacko, CDM, MBA, SHRM-SCP
Global Equity and Learning Partners
Dr. Rosa Colón-Kolacko is the President and Founder of Global Equity and Learning Partners (GEL), a consulting and interim leadership practice advancing inclusion, racial and health equity, human-centric AI, talent development, and community engagement across sectors.
She brings 25+ years of global experience spanning Pharmaceuticals, Life Sciences, Health Systems, Academia, Government, Corporate, Energy, and Nonprofits. Rosa has served in multiple C-Suite roles, including Senior VP & Chief DEI and Community Health Officer at Tufts Medicine, SVP & Chief People/Experience Officer at NYC Health + Hospitals, and SVP & Chief Diversity and Learning Officer at Christiana Care Health System where she was among the nation’s first healthcare CDOs. Earlier in her career, she worked at Bristol Myers-Squibb, and SmithKline Beecham (since renamed GlaxoSmithKline), leading cultural transformation, IT-digital Implementations, HR-leadership development, and lean/Six Sigma functions in Asia, Europe, North America, and Puerto Rico.
Rosa has held academic Professorship appointments at Bowling Green State University, Georgetown and Thomas Jefferson University, currently Adjunct Professor at Tufts University School of Medicine and Visiting Researcher, at the Center for Health and Business Department at Bentley University .
Rosa holds a Ph.D. in Organizational Development and Change, an MBA from Henley Business School, Brunel University (UK), a post-graduate Marketing Diploma, SHRM-SCP, CDM, and Patient Professor certificate from the University of Maryland, and AI in Healthcare from Strategy to Implementation at Harvard University, and the AHA Institute for Diversity and Health Equity. She is also an Equity Fellow of the Delaware Community Foundation.
Deeply committed to advancing equity nationally, Rosa is the former President of the MA Health Equity Compact, a coalition of 80+ C-Suite leaders of color driving systemic change through legislation, workforce development, governance, data, and access to care.
Greg Daniel, PhD, MPH
Eli Lilly & Company
Greg Daniel, PhD, MPH
Eli Lilly & Company
Gregory Daniel, PhD, MPH, serves as Vice President, Head of Policy Innovation, Evidence & Engagement at Eli Lilly and Company. In this role, Greg leads efforts in policy innovation and thought leadership, policy evidence development, and external engagement to promote innovation and improve access and affordability in healthcare. Additionally, Greg has led Eli Lilly’s Global Public Policy group, where he led coordination and management of public policy issues to the company and industry in critical areas such as prescription drug pricing, access, affordability, and global value-based healthcare.
Beyond his leadership at Eli Lilly, Greg contributes extensively to the scientific and policy fields. He is the Editor-in-Chief of Therapeutic Innovation and Regulatory Science (TIRS), the scientific, peer-reviewed journal of DIA. He also serves on the Board of Directors and is a Past Chair for the Center for Innovation & Value Research (CIVR). His academic contributions include roles as Adjunct Associate Professor at the Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, and Visiting Scholar at the Center of Innovation in Regulatory Science at the Duke-National University of Singapore.
Greg has 25 years of experience and expertise leading pharmaceutical and medical device evidence and public policy. Prior to joining Lilly, he held leadership and executive roles within the medical device industry, academia, policy think tanks, and the commercial payer industry. At Edwards Lifesciences, he was Head of US Healthcare Policy. He also held roles as Deputy Center Director and Clinical Professor at the Duke-Margolis Institute for Health Policy, and as Fellow and Managing Director at the Center for Health Policy at the Brookings Institution. Prior to that, Greg directed real-world evidence generation, health economics and outcomes research, and pharmacoepidemiology studies as Vice President, Government and Academic Research, at Carelon (formerly HealthCore and a subsidiary of Elevance).
Greg earned his PhD in pharmaceutical economics, policy, and outcomes from the University of Arizona. Additionally, he holds an MPH with a focus in biostatistics, along with an MS and BS in Pharmacy, all from The Ohio State University.
Lisa Feng, DrPH (Board Liaison)
Alexion, AstraZeneca Rare Disease
Lisa Feng, DrPH (Board Liaison)
Alexion, AstraZeneca Rare Disease
Lisa Feng, DrPH is the Senior Director of Health Policy at Alexion, AstraZeneca Rare Disease which focuses on transforming the lives of people affected by rare diseases and devastating conditions. In her role at Alexion, Dr. Feng helps the company assess the evolving health policy landscape to lead efforts that help ensure patient access to current and future innovations. Prior to Alexion, Dr. Feng was Senior Director of Policy and Advocacy at the Cystic Fibrosis Foundation, where she led state and federal policy analysis and advocacy related to access to cystic fibrosis care and treatments. Dr. Feng was also responsible for the Value and Coverage program at FasterCures, a center of the Milken Institute. She has worked extensively on programs funded by the Center for Medicare and Medicaid Innovation and the Robert Wood Johnson Foundation. Dr. Feng is a health services researcher and has published on topics such as health care quality, diffusion of innovation, and health information technology. She received her doctorate in health policy at the George Washington University Milken Institute School of Public Health.
Christina Hochul, JD, LLM
Astellas
Christina Hochul, JD, LLM
Astellas
Christina Hochul has over 15 years of experience in government affairs and public policy. She is currently the Director of Government Affairs and Policy at Astellas, where she analyzes federal and state regulations and advises the business on their impact. Previously, she held roles in strategic alliances and public policy at Alexion, AstraZeneca Rare Disease, and Biogen. Christina holds a Master of Laws in Intellectual Property from George Washington University Law School and a Juris Doctor from the University of Dayton School of Law. She is actively involved in professional organizations, including serving as a past chair of the Alliance Development Committee for the Biotechnology Innovation Organization (BIO), and has received multiple awards for her leadership in corporate affairs and public policy.
Jennifer Houlihan, MSP
Advocate Health
Jennifer Houlihan, MSP
Advocate Health
Jennifer serves as a vice president for enterprise population health focused on Medicaid and Medicare value-based care policy and programming and integration of the enterprise population health platform with the academic core of Advocate Health. Jennifer is focused on executing aligned learning health system priorities including serving as a member of Wake Forest School of Medicine Center for Healthcare Innovation to test, implement, and scale initiatives that currently include new risk segmentation models and care model innovation focused on healthy aging, risk segmentation, complex care and chronic kidney disease.
Jennifer is a graduate of Florida State University and Thomas Jefferson University with degrees in Healthy Policy and Planning and Population Health.
Fauzea Hussain, MPH
McKesson
Fauzea Hussain, MPH
McKesson
Fauzea Hussain is the Vice President of Public Policy at McKesson, where she champions innovative public policy strategies that drive the company's mission to improve health outcomes for all. With a keen focus on patient-first solutions, Fauzea collaborates across the McKesson enterprise to address the diverse needs of distributors, wholesalers, community providers, health systems, pharmacies, manufacturers, technology vendors, and consumers. During the COVID-19 pandemic, she elevated McKesson's role as a trusted public health partner for the Federal government, states, and underserved communities.
A seasoned policy expert with over 25 years of experience, Fauzea has a proven track record in assessing the impact of state and federal policies on patient access, provider reimbursement, and the life sciences industry. Before joining McKesson, she led Avalere's Reimbursement and Market Access team, where she developed groundbreaking market access strategies for drugs, biologics, devices, and technologies.
Fauzea's career began as the Assistant Director of Reimbursement Policy for the American Academy of Physician Assistants, where she honed her expertise in payment issues. A dedicated patient advocate, she serves on the board of the Cancer Support Community, a leading patient advocacy organization.
Anna Hyde, MA
Arthritis Foundation
Anna Hyde, MA
Arthritis Foundation
Anna Hyde is the Vice President of Advocacy and Access at the Arthritis Foundation. She oversees both the federal and state legislative programs, in addition to grassroots engagement. Her focus is to raise the visibility of arthritis as a public health priority, build support for federal and state legislation that ensure access to affordable, high-quality health care, and enhance patient engagement in the policy-making process. Anna previously served as Senior Director of Advocacy and Access, managing the federal affairs portfolio and overseeing the state advocacy team.
Prior to joining the Arthritis Foundation in 2014, Anna worked as Senior Manager for Federal Affairs at the American Congress of Obstetricians and Gynecologists, where she managed a portfolio of issues including appropriates, physician workforce, and health IT. She began her health policy career as a Congressional Fellow for Energy and Commerce Committee members, where she drafted legislation and staffed Committee activities. Anna received her BA in History from Southern Methodist University, and taught junior high and high school history before moving to Washington, D.C. in 2007 to pursue an MA in Political Science from American University.
Imomotimi (Timmy) Imomotebegha, MSc, MS
The George Washington University
Imomotimi (Timmy) Imomotebegha, MSc, MS
The George Washington University
Timmy Imomotebegha is a research operations and policy leader with over a decade of experience advancing public health and medical research, evidence-to-policy translation, and community-engaged innovation at leading R1 institutions. He currently serves as Senior Research Operations Specialist at the George Washington University’s Milken Institute School of Public Health, where he supports a research enterprise spanning 30+ centers and programs and partners with senior leadership to strengthen research governance, integrity, and public impact.
Timmy works at the intersection of evidence, ethics, equity, and policy, designing systems that improve research efficiency, compliance outcomes, interdisciplinary collaboration, and the policy relevance of patient-centered research. He has contributed to multimillion-dollar proposals, supported cross-sector partnerships, and helped elevate research portfolios addressing health equity, chronic disease, infectious disease, and community-informed outcomes.
His current research interests focus on ethical AI policy frameworks in public health, with an emphasis on transparency, bias mitigation, accountability, and community oversight to ensure AI-enabled health decisions improve value and patient outcomes without widening inequities.
Richie Kahn, MPH
Canary Advisors
Richie Kahn, MPH
Canary Advisors
A health policy professional by training, clinical researcher by trade and patient advocate by necessity, Richie Kahn has spent the last 15 years working across the industry to reduce the time it takes to bring promising new treatments to the patients that need them most. As Co-Founder & COO of Canary Advisors, Richie partners with biopharma, nonprofit, and regulatory stakeholders to better align clinical development programs with patient wants and needs.
Silas Martin
J&J Innovative Medicine
Silas Martin
J&J Innovative Medicine
Silas Martin is the Head of Access and Policy Research at Johnson & Johnson Innovative Medicine and the Scientific Lead for the J&J Center for U.S. Healthcare Policy Research. In this role, he guides a multidisciplinary team dedicated to leading rigorous research and scientific engagement with researchers, economists, and policy experts across the healthcare system. His work focuses on shaping forward-looking health policies that enable patient access to transformational innovation today and in the future.
Through his leadership at the J&J Center, Silas drives the mission to lead robust scientific research to support the development of evidence-based policies that accelerate medical innovation and enhance patient value, access and affordability. The J&J Center serves as a hub for policy evidence to strengthen the healthcare ecosystem and improve patient outcomes.
Silas has dedicated his career at Johnson & Johnson to improving patient lives, through work spanning health economics, outcomes research, market access, and healthcare policy. He has published extensively across these disciplines, contributing insights that support more equitable and sustainable approaches to healthcare delivery and innovation.
Silas earned a Bachelor of Arts from Cornell University and a Master of Science in Evaluative Clinical Sciences from Dartmouth, where he developed expertise in evidence generation, policy analysis, and health systems research.
Claire Sachs, MA
TPAC Consulting
Claire Sachs, MA
TPAC Consulting
Claire is a federal health policy and communications specialist whose personal health history goes back to the early 1980s. Since then, she has managed a raft of serious conditions, both acute and chronic. She has also been a caregiver for both chronically ill and terminally ill family members.
A few years ago, Claire realized her experience with healthcare could be used to help patients, so she founded the patient advocacy blog, The Patient Advocate’s Chronicle, and the healthcare experience consultancy, TPAC Consulting, which aims to make positive changes to the healthcare ecosystem by offering the patient perspective to non-patient stakeholders who want to improve patient outcomes.
Claire has participated in advisory councils for the Chronic Disease Coalition, ABIM Foundation, United States of Care, Maryland Department of Health Diabetes Quality Task Force, and the Center for Innovation and Value Research. She has also worked with the Right Care Alliance, FamiliesUSA, Georgetown Medical School, and the Diabetes Patient Advocacy Coalition.
Claire has a BA in Government from Smith College and an MA in Political Management from George Washington University.
Daneen Sekoni
Cancer Support Community
Daneen Sekoni
Cancer Support Community
As Vice President of Policy and Advocacy at Cancer Support Community, she leads policy and advocacy efforts and advances initiatives that ensure that the voices of patients, caregivers, and survivors continue to shape policymaking. Prior to joining CSC, Daneen served as the staff lead for the MultiCancer Early Detection (MCED) Consortium’s Health Equity Workgroup and led the Policy and Advocacy team for the Coalition to End Social Isolation and Loneliness, where she provided strategic direction and policy analysis on issues including mental health, caregivers, and social connection. She also served as Director of Health Care Reform Policy at the American Speech-Language-Hearing Association, where her efforts led to patients gaining access to habilitation and rehabilitation services and receiving in every health insurance plan’s Summary of Benefits & Coverage the details of what services are covered and how many are covered. In addition, Daneen worked to promote and protect the healthcare rights of all patients and caregivers by ensuring that individuals with limited English proficiency and individuals with disabilities had the availability of language assistance services and/or auxiliary aids and services to enable them to identify themselves, participate in and understand their healthcare.